HUTCHMED (China) LtdHCMEarnings & Financial Report
HUTCHMED (China) Ltd is a biopharmaceutical firm focused on discovering, developing and commercializing targeted and immunotherapies for oncology and immunological diseases. It operates across China and global markets, with multiple marketed oncology drugs and a robust pipeline of late-stage clinical candidates addressing unmet patient needs.
Revenue
$324.5M
Gross Profit
$155.8M
Operating Profit
$-16.2M
Net Profit
$11.9M
Gross Margin
48.0%
Operating Margin
-5.0%
Net Margin
3.7%
YoY Growth
N/A
EPS
$0.01
Financial Flow
HUTCHMED (China) Ltd Q4 2024 Financial Summary
HUTCHMED (China) Ltd reported revenue of $324.5M for Q4 2024, with a net profit of $11.9M (3.7% margin). Cost of goods sold was $168.7M, operating expenses totaled $172.0M.
Key Financial Metrics
| Total Revenue | $324.5M |
|---|---|
| Net Profit | $11.9M |
| Gross Margin | 48.0% |
| Operating Margin | -5.0% |
| Report Period | Q4 2024 |
HUTCHMED (China) Ltd Quarterly Revenue & Net Profit History
HUTCHMED (China) Ltd results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $270.8M | -16.5% | $2.0M | 0.7% |
| Q2 2025 | $277.7M | -9.2% | $455.0M | 163.8% |
| Q4 2024 | $324.5M | — | $11.9M | 3.7% |
| Q2 2024 | $305.7M | -42.6% | $25.8M | 8.4% |
| Q2 2023 | $532.9M | +163.7% | $168.6M | 31.6% |
| Q2 2022 | $202.0M | +28.4% | $-162.9M | -80.6% |
Income Statement
| Q2 2022 | Q2 2023 | Q2 2024 | Q4 2024 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $202.0M | $532.9M | $305.7M | $324.5M | $277.7M | $270.8M |
| YoY Growth | 28.4% | 163.7% | -42.6% | N/A | -9.2% | -16.5% |
Balance Sheet
| Q2 2022 | Q2 2023 | Q2 2024 | Q4 2024 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Assets | $1.19B | $1.30B | $1.26B | $1.27B | $1.78B | $1.75B |
| Liabilities | $342.5M | $497.5M | $508.9M | $502.3M | $534.0M | $501.8M |
| Equity | $799.7M | $782.0M | $740.1M | $759.9M | $1.23B | $1.24B |
Cash Flow
| Q2 2022 | Q2 2023 | Q2 2024 | Q4 2024 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $-89.9M | $226.4M | $-39.8M | $40.3M | $-72.9M | $8.2M |